Katherine Stueland Sells 46,594 Shares of GeneDx Holdings Corp. (NASDAQ:WGS) Stock

GeneDx Holdings Corp. (NASDAQ:WGS) CEO Katherine Stueland sold 46,594 shares of the firm’s stock in a transaction on Wednesday, April 9th. The stock was sold at an average price of $89.62, for a total transaction of $4,175,754.28. Following the transaction, the chief executive officer now directly owns 1,720 shares in the company, valued at $154,146.40. The trade was a 96.44 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.

Katherine Stueland also recently made the following trade(s):

• On Wednesday, March 26th, Katherine Stueland sold 46,551 shares of GeneDx stock. The stock was sold at an average price of $95.62, for a total value of $4,451,206.62.
• On Thursday, March 13th, Katherine Stueland sold 1,078 shares of GeneDx stock. The stock was sold at an average price of $89.44, for a total value of $96,416.32.
• On Monday, March 17th, Katherine Stueland sold 10,559 shares of GeneDx stock. The stock was sold at an average price of $96.71, for a total transaction of $1,021,160.89.
• On Monday, March 10th, Katherine Stueland sold 2,731 shares of GeneDx stock. The stock was sold at an average price of $94.73, for a total transaction of $258,707.63.
• On Wednesday, January 29th, Katherine Stueland sold 1,657 shares of GeneDx stock. The stock was sold at an average price of $78.48, for a total transaction of $130,041.36.

GeneDx Price Performance

Shares of NASDAQ:WGS opened at $96.63 on Friday. The firm has a market capitalization of $2.71 billion, a price-to-earnings ratio of -49.30 and a beta of 1.93. The company has a debt-to-equity ratio of 0.25, a current ratio of 2.40 and a quick ratio of 2.27. The business’s 50 day simple moving average is $90.43 and its 200-day simple moving average is $78.11. GeneDx Holdings Corp. has a 12 month low of $8.63 and a 12 month high of $115.60.

GeneDx (NASDAQ:WGS) last posted its earnings results on Tuesday, February 18th. The company reported $0.70 earnings per share for the quarter, beating the consensus estimate of $0.04 by $0.66. The company had revenue of $95.64 million for the quarter, compared to analyst estimates of $82.24 million. GeneDx had a positive return on equity of 3.33% and a negative net margin of 17.12%. As a group, equities analysts forecast that GeneDx Holdings Corp. will post 0.97 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts have issued reports on the company. TD Cowen boosted their target price on GeneDx from $75.00 to $118.00 and gave the stock a “buy” rating in a research report on Tuesday, January 7th. The Goldman Sachs Group increased their price objective on GeneDx from $70.00 to $80.00 and gave the stock a “neutral” rating in a research report on Wednesday, February 19th. Three investment analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. According to data from MarketBeat.com, GeneDx currently has an average rating of “Moderate Buy” and an average target price of $72.33.

Hedge Funds Weigh In On GeneDx

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. MCF Advisors LLC increased its stake in shares of GeneDx by 107.7% during the 4th quarter. MCF Advisors LLC now owns 351 shares of the company’s stock worth $27,000 after purchasing an additional 182 shares in the last quarter. Sterling Capital Management LLC grew its holdings in GeneDx by 877.8% during the 4th quarter. Sterling Capital Management LLC now owns 352 shares of the company’s stock valued at $27,000 after buying an additional 316 shares during the last quarter. Global Retirement Partners LLC purchased a new position in GeneDx during the fourth quarter worth $28,000. Lazard Asset Management LLC acquired a new position in shares of GeneDx in the fourth quarter worth $35,000. Finally, Comerica Bank purchased a new stake in shares of GeneDx in the fourth quarter valued at $50,000. Institutional investors and hedge funds own 61.72% of the company’s stock.

About GeneDx

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.